SEARCH
ENGLISH
When it comes to innovative peptide drug development, pharmaceutical scientists must go beyond traditional peptide technology. “Multifunctional peptides” with multiple pharmacological activities are one of the most representative fields of non-specific drugs and have given rise to dual-function and three-function peptides. Pegcetacoplan and Tirzepatide, approved for marketing in 2021 and 2022 respectively, have put multifunctional peptides on the official stage.
As a China peptide company, we would like to share with our customers the detailed definition and types of peptides.
Multifunctional peptides are polypeptide molecules that contain two or more peptide polypeptide sequences that are coupled and targeted to multiple targets, with multiple pharmacological activities, and whose different mechanisms synergistically enhance efficacy while minimizing side effects. They are particularly suitable for treating diseases with complex mechanisms, such as cardiovascular diseases, metabolic diseases, neurological diseases, and tumors.
The development of multifunctional peptides requires in-depth research based on “genomic information” and “disease biology”. They simultaneously activate different signaling pathways to maximize biological activity, minimize side effects, and provide more balanced pharmacokinetics, offering patients systemic and multitarget therapeutic options. Multifunctional peptides are the most representative frontier area of the new economy of peptide polypeptides.
According to molecular type, multifunctional peptides can be divided into multifunctional fusion peptides, multifunctional connecting peptides, multifunctional chimeric peptides, multifunctional stapling peptides, multifunctional cyclic peptides, and bicyclic peptides. The most extensively researched techniques currently include fusion peptide technology, connecting peptide technology, chimeric peptide technology, and bicyclic peptides (bicyclic peptides, cyclic peptides, stapling peptides, and cyclic stapling peptides are also called “constrained peptides”). We even have cosmetic peptides for sale.
Compared to single-function peptides, multifunctional peptides simultaneously activate different signaling pathways to maximize biological activity, maintain the best safety or antagonistic toxic side effects, and present a more balanced PK behavior. Compared to combination therapy, multifunctional peptides avoid complex drug-drug interactions and the complex PK/PD behavior that arises from single-drug combination therapy, making the therapy safer, and increasing patient and physician compliance.
As of now, there are approximately 24 multifunctional peptides in clinical development worldwide (including 2 marketed products). We can provide you with a detailed peptide drugs list. The most representative global multifunctional peptide companies include Eli Lilly, MacroGenics, Apellis, Hammi, AstraZeneca, Amgen, etc. Statistics show that dual-function and three-function peptides from major pharmaceutical companies around the world are mainly focused on diabetes, obesity, and NASH, with fierce competition in indication selection. Only Apellis, MacroGenics, and Bioniz have taken a different approach, creating differentiated banners and pushing multifunctional peptides into different treatment areas.
English 
